MedTrace Logo

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2013-11-15

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

AGN-214868

AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.

DRUG

Placebo to AGN-214868

Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-10-31
Completion
2012-01-31

Countries

  • United States
  • Czechia
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129531 on ClinicalTrials.gov